We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Alinidine, a new agent which lowers heart rate in patients with angina pectoris.
- Authors
SIMOONS, M. L.; TUMMERS, J.; VAN MEURS-VAN WOEZIK, H.; VAN DOMBURG, R.
- Abstract
Alinidine has been shown to reduce heart rate in experimental animals and in humans. However, in contrast with the beta blockers, this effect is not mediated through adrenergic receptors. The potential value of this drug was tested in eight patients with coronary artery disease and stable angina pectoris. During a one-week period of hospitalisation, exercise tests were done on four successive days after administration of placebo, 20, 40 and 60 mg alinidine, in a randomized double-blind sequence. On each day, exercise tests were performed on a bicycle ergometer with workload increments of 20 W/min until angina or fatigue. A dose-dependent reduction of heart rate and of the rate-pressure product was observed after alinidine. Rate-pressure products at peak exercise were 242 ± 42, 218 ± 29, 206 ± 33 and 197 ± 33 after placebo and ascending doses of alinidine, respectively. Exercise tolerance improved by a mean of 16 W, while the highest load which was achieved without symptoms improved by 26 W with 60 mg of alinidine. It is concluded that alinidine reduces myocardial oxygen consumption and improves exercise tolerance in patients with angina. Its ultimate clinical value should be further evaluated in larger groups of patients.
- Publication
European Heart Journal, 1982, Vol 3, Issue 6, p542
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/oxfordjournals.eurheartj.a061350